Serum biomarkers confirming stable remission in inflammatory bowel disease

Kessel, Christoph; Lavrič, Miha; Weinhage, Toni; Brüeckner, Markus; Roock, Sytze de; Däbritz, Jan; Weber, Jakob; Vastert, Sebastiaan J.; Foell, Dirk

doi:10.1038/s41598-021-86251-w

Cited by 33 publications

(28 citation statements)

References 37 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…TLR4 signaling is required for the induction of NEC in both mice and patients [24]. Elevated levels of proinflammatory cytokines have been observed in chronic inflammatory bowel disease and correlate with the intensity of inflammation [25].…”

Section: Discussionmentioning

confidence: 99%

Sodium Butyrate Alleviates Intestinal Inflammation in Mice with Necrotizing Enterocolitis

Sun

Wang

et al. 2021

Mediators of Inflammation

View full text Add to dashboard Cite

Objective. To determine the role of sodium butyrate in intestinal inflammation via regulation of high-mobility group box-1 (HMGB1), we analyzed the potential mechanism in necrotizing enterocolitis (NEC) in a neonatal mouse model. Methods. A NEC model was created with hypoxia and cold exposure and artificial overfeeding. C57BL/6 neonatal mice were randomized into three groups: the control, untreated NEC, and sodium butyrate (150 mM)-pretreated NEC groups. Pathological variations in ileocecal intestinal tissue were observed by HE staining and scored in a double-blind manner. The mRNA expression levels of HMGB1, Toll-like receptor 4 (TLR4), nuclear factor-κB (NF-κB), and inflammatory cytokines in intestinal tissues were determined by quantitative real-time PCR. The protein levels of HMGB1 and associated cytokines in intestinal tissues were evaluated using ELISA. The relative protein expression levels of TLR4 and NF-κB in intestinal tissues were quantified by western blot. Results. Sodium butyrate administration improved the body weight and survival rate of NEC mice; relieved intestinal pathological injury; reduced the intestinal expression of HMGB1, TLR4, NF-κB, interleukin- (IL-) 1β, IL-6, IL-8, and TNF-α; and increased the intestinal expression of IL-10 ( P < 0.05 ). Treatment with butyrate decreased the proportion of opportunistic Clostridium_sensu_stricto_1 and Enterococcus and increased the proportion of beneficial Firmicutes and Lactobacillus in the NEC model. Conclusions. Sodium butyrate intervention relieves intestinal inflammation and partially corrects the disrupted intestinal flora in mice with NEC.

show abstract

Section: Discussionmentioning

confidence: 99%

Sodium Butyrate Alleviates Intestinal Inflammation in Mice with Necrotizing Enterocolitis

Sun

Wang

et al. 2021

Mediators of Inflammation

View full text Add to dashboard Cite

show abstract

“…Despite the fact that colonoscopy is the best approach for diagnosing IBD, it is intrusive and costly, hence an urgent demand for non-invasive, accepted, and accurate blood-based biomarkers has emerged [4] . CRP and ESR, two serum indicators of acute phase response, are too little sensitive and specific for intestinal inflammation since their levels are frequently elevated in infections, autoimmune disorders, and other conditions [13] . Serum calprotectin has been investigated as an acute phase reactant increasing with IBD exacerbations [11] .…”

Section: Discussionmentioning

confidence: 99%

Serum Calprotectin: A promising Biomarker for Inflammatory Bowel Disease (IBD)

Azab

Talkhan

Samaha

et al. 2021

International Journal of Medical Arts

View full text Add to dashboard Cite

Article informationBackground: These days, inflammatory bowel disease [IBD] is growing more common.Its diagnosis relies on invasive techniques like colonoscopy and biopsy, and its activity is monitored by fecal calprotectin levels that have a low compliance rate, so there is a pressing need for a serum biomarker that is non-invasive, accepted, and accurate for diagnosing and monitoring IBD activity. The aim of the work: The goal of our research is to study serum calprotectin as a candidate biomarker in IBD. Methods: The study included 50 patients with IBD who were recruited from Ain Shams University Hospitals' Gastroenterology clinic. Sixty percent were diagnosed with ulcerative colitis, with half in activity and the other half in remission, and 40% were diagnosed with Chron's disease, with half in activity and the other half in remission.A control group of 20 apparently healthy individuals comparable in age and sex were also included in the study. All subjects had their serum calprotectin tested by ELISA in addition to their ESR and CRP measurements. Results: Serum calprotectin levels were significantly higher in patients with IBD than in controls and in clinically active patients than those in remission in both UC and CD groups. Although there was a positive association between serum calprotectin levels and CRP and ESR, serum calprotectin had a higher diagnostic value than CRP and ESR due to its higher sensitivity and specificity. Our findings demonstrated that serum calprotectin and platelet count had a direct relationship, while serum calprotectin and serum albumin and hemoglobin levels had an inverse relationship. Conclusion: Serum calprotectin levels are raised and linked to clinical activity in IBD patients, implying that it could be utilised as a clinically useful indicator of disease activity.

show abstract

“…In our study, full remission was defined based on clinical remission and biochemical markers within normal limits. Accordingly, clinical remission was defined as a Crohn’s disease activity index (CDAI) ≤ 150 for CD patients and Mayo Clinic score ≤ 2 for UC patients, respectively [ 19 , 20 ]. Biochemical remission in our evaluation was defined as a normal CRP (≤ 5 mg/L) and fecal calprotectin (≤ 150 μg/g stool) [ 21 , 22 ].…”

Section: Methodsmentioning

confidence: 99%

Serum procalcitonin levels associate with Clostridioides difficile infection in patients with inflammatory bowel disease

et al. 2021

View full text Add to dashboard Cite

Background Clostridioides difficile infection (CDI) is a major cause of morbidity among patients with inflammatory bowel disease (IBD). Diagnostic biomarkers for early detection of CDI are needed in clinical practice. The relationship between serum procalcitonin and CDI in IBD patients has not been investigated so far. Therefore, we aimed to evaluate the usefulness of measuring serum procalcitonin level to detect CDI in patients with the flare of IBD. Methods One hundred twenty patients with IBD were enrolled in this study. Bacterial identification was performed using standard microbiological and molecular methods. The serum procalcitonin levels were measured in all patients. Receiver operating characteristic (ROC) curve analysis was applied to assess the value of procalcitonin for the prediction of CDI among IBD patients. Results The median serum procalcitonin level was significantly increased in IBD patients with CDI compared to non-CDI IBD patients (0.69 ng/mL vs 0.32 ng/mL). In univariate analysis, log10 procalcitonin was associated with CDI (OR 2.81, 95% CI 1.54–4.09, P-value < 0.001). Procalcitonin 1.1 ng/mL was 85% sensitive and 88% specific for the prediction of CDI. In the multivariable model including the covariates log10 procalcitonin, age, hospitalization, type of IBD, duration of the disease, and antibiotic usage, procalcitonin showed a robust association with CDI (OR 4.59, 95% CI 2.49–6.70, P-value < 0.001). An elevated procalcitonin level was associated with the presence of CDI among IBD patients. Conclusions Our results indicate that procalcitonin level can be a good candidate biomarker for assessing the CDI in IBD patients. Further studies are required to decipher whether procalcitonin can predict CDI therapy or its recurrence.

show abstract

Serum biomarkers confirming stable remission in inflammatory bowel disease

Cited by 33 publications

References 37 publications

Sodium Butyrate Alleviates Intestinal Inflammation in Mice with Necrotizing Enterocolitis

Sodium Butyrate Alleviates Intestinal Inflammation in Mice with Necrotizing Enterocolitis

Serum Calprotectin: A promising Biomarker for Inflammatory Bowel Disease (IBD)

Serum procalcitonin levels associate with Clostridioides difficile infection in patients with inflammatory bowel disease

Contact Info

Product

Resources

About